Larsulin

Larsulin^TM
12
LarsulinTM
Insulin Glargine
Anti-diabetic (Analogue Insulin)
Indication: Type 1 and Type 2 Diabetes Mellitus.

Dosage & Administration: LarsulinTM exhibits a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing. Potency of insulin glargine is approximately the same as human insulin.
LarsulinTM is recommended for once daily subcutaneous administration & may be administered at any time during the day. However, once started should be administered at the same time every day.
The dose of LarsulinTM must be individualized based on clinical response. Blood glucose monitoring is essential in all patients with diabetes. In patients with type 1 diabetes, LarsulinTM must be used in regimens with short-acting insulin. LarsulinTM is not recommended for intravenous administration.
Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia.

Initiation of LarsulinTM therapy:
The recommended starting dose of LarsulinTM in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements.
The recommended starting dose of LarsulinTM in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted to the patient’s needs.

Converting to LarsulinTM from other insulin therapies
If changing from a treatment regimen with an intermediate-or long-acting insulin to a regimen with LarsulinTM , the amount and timing of shorter-acting insulins and doses of any oral anti-diabetic drugs may need to be adjusted.
If transferring patients from once-daily NPH insulin to once-daily LarsulinTM, the recommended initial LarsulinTM dose is the same as the dose of NPH that is being discontinued.
If transferring patients from twice-daily NPH insulin to once-daily LarsulinTM, the recommended initial LarsulinTM dose is 80% of the total NPH dose that is being discontinued.

Preparation:
LarsulinTM Injection: Each box contains 3 ml glass vial.
LarsulinTM Pen Cartridge: Each box contains 3 ml glass Cartridge.